ATyr Pharma’s stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates.
ATyr Pharma’s stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates.
Copyright © Louis Velazquez. All Rights Reserved.